Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THRX
14.30
+0.39 (2.80%)
Sep 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.46 - 14.39
52 week 10.58 - 23.84
Open 13.56
Vol / Avg. 2.11M/553,712.00
Mkt cap 1.63B
P/E     -
Div/yield 0.25/6.99
EPS -0.49
Shares 117.02M
Beta 2.12
Inst. own 86%
Oct 28, 2015
Q3 2015 Theravance Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 9, 2015
Theravance Inc at Robert W Baird and Co Health Care Conference - 9:05AM EDT - Add to calendar
Jul 29, 2015
Q2 2015 Theravance Inc Earnings Call - Webcast
Jul 29, 2015
Q2 2015 Theravance Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -73.30% -871.93%
Operating margin 47.94% -402.34%
EBITD margin - -257.96%
Return on average assets -6.59% -12.23%
Return on average equity - -194.08%
Employees 10 -
CDP Score - -

Address

951 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. is a royalty management company. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI), with the intention of providing capital returns to stockholders. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2 agonist (LABA) and fluticasone furoate (FF), an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA) for the treatment of chronic obstructive pulmonary diseases (COPD). BREO ELLIPTA and ANORO ELLIPTA are not indicated for the relief of acute bronchospasm or the treatment of asthma in the United States and Canada.

Officers and directors

William H. Waltrip Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 60
Bio & Compensation  - Reuters
Michael E. Faerm Senior Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Catherine J. Friedman Independent Director
Age: 54
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 60
Bio & Compensation  - Reuters
Paul Pepe Independent Director
Age: 56
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 62
Bio & Compensation  - Reuters